Compare BIPC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIPC | DYN |
|---|---|---|
| Founded | 2019 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.9B |
| IPO Year | 2019 | 2020 |
| Metric | BIPC | DYN |
|---|---|---|
| Price | $40.82 | $25.96 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $45.00 | $37.00 |
| AVG Volume (30 Days) | 816.4K | ★ 2.6M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $5.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $8.88 |
| 52 Week High | $51.72 | $25.00 |
| Indicator | BIPC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 68.05 |
| Support Level | $37.42 | $16.47 |
| Resistance Level | $42.84 | N/A |
| Average True Range (ATR) | 0.84 | 1.43 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 57.99 | 86.58 |
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.